REGENXBIO Inc. (RGNX) Receives $41.67 Consensus Price Target from Brokerages
REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $41.67.
Several research analysts have weighed in on RGNX shares. Zacks Investment Research cut REGENXBIO from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Chardan Capital reiterated a “buy” rating and set a $75.00 price objective (up previously from $55.00) on shares of REGENXBIO in a research report on Tuesday, September 5th. BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Finally, Evercore ISI started coverage on REGENXBIO in a research report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective on the stock.
In related news, CFO Vittal Vasista sold 3,100 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $19.81, for a total value of $61,411.00. Following the transaction, the chief financial officer now owns 108,423 shares in the company, valued at $2,147,859.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kenneth T. Mills sold 6,500 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $19.68, for a total value of $127,920.00. Following the completion of the transaction, the insider now owns 119,396 shares in the company, valued at approximately $2,349,713.28. The disclosure for this sale can be found here. Insiders have sold a total of 119,240 shares of company stock worth $2,824,685 in the last quarter. Company insiders own 17.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc increased its position in shares of REGENXBIO by 41.4% in the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares during the period. Oxford Asset Management bought a new position in shares of REGENXBIO in the first quarter worth $206,000. American International Group Inc. increased its position in shares of REGENXBIO by 7.1% in the first quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 822 shares during the period. Voya Investment Management LLC bought a new position in shares of REGENXBIO in the second quarter worth $249,000. Finally, Acadian Asset Management LLC bought a new position in shares of REGENXBIO in the first quarter worth $272,000. Institutional investors own 73.23% of the company’s stock.
REGENXBIO (NASDAQ:RGNX) traded up 4.31% during midday trading on Friday, reaching $26.60. 176,863 shares of the company’s stock were exchanged. REGENXBIO has a 12 month low of $13.61 and a 12 month high of $26.65. The company has a 50 day moving average price of $25.58 and a 200 day moving average price of $20.97. The company’s market cap is $821.78 million.
REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.34. The firm had revenue of $6.56 million for the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. On average, equities analysts anticipate that REGENXBIO will post ($2.87) EPS for the current year.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.